RecruitingNCT06596746
Rare condition
Dietary iron overload disease
5
studies recruiting now
as of 7 Sept 2026
45
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
19 Jun 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07028112
Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.
RecruitingPhase 2NCT07023666
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
RecruitingNCT05335603
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
RecruitingNCT03131427
China Registry for Genetic / Metabolic Liver Diseases
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Dietary iron overload disease studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Dietary iron overload disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Dietary iron overload disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Deferasirox (Deferasirox)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).